|
![]() |
貨號 | 品名 | 規(guī)格 | 包裝 | 單價 | 貨期 | 庫存 |
JD200512093117 | 帕妥珠單抗 | 99.10% | 5mg | 11400元 | 咨詢客服 | 3天 |
JD200512093059 | 帕妥珠單抗 | 99.10% | 1mg | 5800元 | 咨詢客服 | 3天 |
性狀: | Pertuzumab 是一種人源化單克隆抗體,是一種HER2二聚抑制劑??捎糜谥委熮D(zhuǎn)移性HER2 陽性乳腺癌。 |
質(zhì)量標(biāo)準(zhǔn): | Description Pertuzumab, a humanized monoclonal antibody, is a HER2 dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer. IC50 & Target EGFR[1] Storage Please store the product under the recommended conditions in the Certificate of Analysis. References [1]. Nahta R, et al. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survivalof breast cancer cells. Cancer Res. 2004 Apr 1;64(7):2343-6. [2]. Scheuer W, et al. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res. 2009 Dec 15;69(24):9330-6. |